Table 1.
Demographic Characteristics of Samples Included in the Meta-Analysis
| Treatment Group | Control Group | Total | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Studies | Participants | Mean | SD | Studies | Participants | Mean | SD | Studies | Participants | |
| Age (y) | 37.14 | 7.94 | 68 | 2253 | 37.35 | 7.90 | 68 | 2032 | 37.18 | 7.53 | 73 | 4594 |
| Gender (% males) | 67.25 | 14.55 | 64 | 2120 | 65.84 | 14.47 | 64 | 1937 | 66.49 | 13.35 | 68 | 4332 |
| Education (y) | 11.69 | 1.53 | 56 | 1892 | 11.73 | 1.34 | 56 | 1678 | 11.74 | 1.36 | 60 | 3794 |
| Illness duration (y) | 12.46 | 7.86 | 45 | 1473 | 12.41 | 7.80 | 45 | 1331 | 12.54 | 7.56 | 47 | 2935 |
| PANSS positive | 15.68 | 4.73 | 39 | 1335 | 15.39 | 4.83 | 39 | 1219 | 15.77 | 4.85 | 41 | 2731 |
| PANSS negative | 18.04 | 4.46 | 38 | 1261 | 18.30 | 4.60 | 38 | 1143 | 18.43 | 4.58 | 40 | 2581 |
| IQ | 96.47 | 6.86 | 34 | 1106 | 96.05 | 8.66 | 34 | 1005 | 96.19 | 7.30 | 35 | 2171 |
| Chlorpromazine equivalents (mg/d) | 552.57 | 288.99 | 30 | 1074 | 568.70 | 424.21 | 30 | 973 | 563.70 | 326.21 | 31 | 2131 |
| Racial distribution (% non-white) | 52.16 | 25.75 | 17 | 525 | 49.83 | 24.30 | 17 | 438 | 52.8 | 27.33 | 22 | 1319 |
Note: PANSS, Positive and Negative Syndrome Scale.